PMID- 12558980
OWN - NLM
STAT- MEDLINE
DCOM- 20030214
LR  - 20190630
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 84
IP  - 3
DP  - 2003 Feb
TI  - Characterization of amyloid beta peptides from brain extracts of transgenic mice 
      overexpressing the London mutant of human amyloid precursor protein.
PG  - 602-9
AB  - Alzheimer's disease (AD) is marked by the presence of neurofibrillary tangles and 
      amyloid plaques in the brain of patients. To study plaque formation, we report on 
      further quantitative and qualitative analysis of human and mouse amyloid beta 
      peptides (Abeta) from brain extracts of transgenic mice overexpressing the London 
      mutant of human amyloid precursor protein (APP). Using enzyme-linked 
      immunosorbant assays (ELISAs) specific for either human or rodent Abeta, we found 
      that the peptides from both species aggregated to form plaques. The ratios of 
      deposited Abeta1-42/1-40 were in the order of 2-3 for human and 8-9 for mouse 
      peptides, indicating preferential deposition of Abeta42. We also determined the 
      identity and relative levels of other Abeta variants present in protein extracts 
      from soluble and insoluble brain fractions. This was done by combined 
      immunoprecipitation and mass spectrometry (IP/MS). The most prominent peptides 
      truncated either at the carboxyl- or the amino-terminus were Abeta1-38 and 
      Abeta11-42, respectively, and the latter was strongly enriched in the extracts of 
      deposited peptides. Taken together, our data indicate that plaques of APP-London 
      transgenic mice consist of aggregates of multiple human and mouse Abeta variants, 
      and the human variants that we identified were previously detected in brain 
      extracts of AD patients.
FAU - Pype, Stefan
AU  - Pype S
AD  - Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen 
      Pharmaceutica, Turnhoutseweg, Beerse, Belgium.
FAU - Moechars, Dieder
AU  - Moechars D
FAU - Dillen, Lieve
AU  - Dillen L
FAU - Mercken, Marc
AU  - Mercken M
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Amyloid beta-Protein Precursor)
RN  - 0 (Peptide Fragments)
RN  - 0 (Tissue Extracts)
RN  - 0 (amyloid beta-protein (1-40))
RN  - 0 (amyloid beta-protein (1-42))
SB  - IM
MH  - Alzheimer Disease/genetics
MH  - Amino Acid Sequence
MH  - Amyloid beta-Peptides/biosynthesis/*chemistry/*metabolism
MH  - Amyloid beta-Protein Precursor/genetics/*metabolism
MH  - Animals
MH  - Brain/metabolism/pathology
MH  - Brain Chemistry
MH  - Disease Models, Animal
MH  - Female
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Molecular Sequence Data
MH  - Mutation
MH  - Peptide Fragments/biosynthesis/*chemistry
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
MH  - Tissue Extracts/*chemistry
EDAT- 2003/02/01 04:00
MHDA- 2003/02/15 04:00
CRDT- 2003/02/01 04:00
PHST- 2003/02/01 04:00 [pubmed]
PHST- 2003/02/15 04:00 [medline]
PHST- 2003/02/01 04:00 [entrez]
AID - 1556 [pii]
AID - 10.1046/j.1471-4159.2003.01556.x [doi]
PST - ppublish
SO  - J Neurochem. 2003 Feb;84(3):602-9. doi: 10.1046/j.1471-4159.2003.01556.x.